CRDF
Price
$3.06
Change
-$0.08 (-2.55%)
Updated
Apr 1 closing price
Capitalization
208.22M
29 days until earnings call
NAMS
Price
$18.39
Change
-$2.08 (-10.16%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
2.02B
35 days until earnings call
Ad is loading...

CRDF vs NAMS

Header iconCRDF vs NAMS Comparison
Open Charts CRDF vs NAMSBanner chart's image
Cardiff Oncology
Price$3.06
Change-$0.08 (-2.55%)
Volume$1.61M
Capitalization208.22M
NewAmsterdam Pharma
Price$18.39
Change-$2.08 (-10.16%)
Volume$47.8K
Capitalization2.02B
CRDF vs NAMS Comparison Chart
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. NAMS commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Buy and NAMS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (CRDF: $3.14 vs. NAMS: $20.47)
Brand notoriety: CRDF and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 78% vs. NAMS: 157%
Market capitalization -- CRDF: $208.22M vs. NAMS: $2.02B
CRDF [@Biotechnology] is valued at $208.22M. NAMS’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 6 bullish TA indicator(s).

  • CRDF’s TA Score: 4 bullish, 6 bearish.
  • NAMS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -17.15% price change this week, while NAMS (@Biotechnology) price change was -14.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

CRDF is expected to report earnings on May 01, 2025.

NAMS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.02B) has a higher market cap than CRDF($208M). NAMS YTD gains are higher at: -20.350 vs. CRDF (-27.650). CRDF has higher annual earnings (EBITDA): -48.25M vs. NAMS (-241.49M). NAMS has more cash in the bank: 834M vs. CRDF (91.7M). NAMS has less debt than CRDF: NAMS (448K) vs CRDF (1.52M). NAMS has higher revenues than CRDF: NAMS (45.6M) vs CRDF (683K).
CRDFNAMSCRDF / NAMS
Capitalization208M2.02B10%
EBITDA-48.25M-241.49M20%
Gain YTD-27.650-20.350136%
P/E RatioN/AN/A-
Revenue683K45.6M1%
Total Cash91.7M834M11%
Total Debt1.52M448K340%
FUNDAMENTALS RATINGS
CRDF: Fundamental Ratings
CRDF
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
PROFIT vs RISK RATING
1..100
90
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRDFNAMS
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
40%
MACD
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 2 days ago
40%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 20 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGREX6.61N/A
N/A
VALIC Company I Global Real Estate
BFGBX38.98N/A
N/A
BlackRock Capital Appreciation K
LFVCX25.67N/A
N/A
Lord Abbett Focused Small Cap Value C
MEMQX7.89N/A
N/A
Mercer Emerging Markets Equity Y3
RSLDX63.67-0.62
-0.96%
American Funds SMALLCAP World R5E

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with CMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-5.93%
CMRX - NAMS
51%
Loosely correlated
+0.12%
QURE - NAMS
50%
Loosely correlated
-15.00%
CRDF - NAMS
34%
Loosely correlated
-4.56%
GYRE - NAMS
32%
Poorly correlated
-15.26%
IMCR - NAMS
28%
Poorly correlated
+0.30%
More